913358-93-7

Basic information

• Product Name: (R)-2-((R)-6,7-diMethoxy-1-(4-(trifluoroMethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-Methyl-2-phenylacetaMide
• Synonyms: Almorexant HCI;(R)-2-((S)-1-(4-(trifluoromethyl)phenethyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide hydrochloride;ACT078573 hydrochloride;AlMorexant (hydrochloride);(alphaR,1S)-3,4-Dihydro-6,7-dimethoxy-N-methyl-alpha-phenyl-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-2(1H)-isoquinolineacetamide monohydrochloride
• CAS NO: 913358-93-7
• Molecular Formula: C₂₉H₃₁F₃N₂O₃*ClH
• Molecular Weight: 512.5632496
• Product Categories: Inhibitors
• Mol File: 913358-93-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (R)-2-((R)-6,7-diMethoxy-1-(4-(trifluoroMethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-Methyl-2-phenylacetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-((R)-6,7-diMethoxy-1-(4-(trifluoroMethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-Methyl-2-phenylacetaMide(913358-93-7)
• EPA Substance Registry System: (R)-2-((R)-6,7-diMethoxy-1-(4-(trifluoroMethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-Methyl-2-phenylacetaMide(913358-93-7)

Safety Data

• Hazardous Substances Data: 913358-93-7(Hazardous Substances Data)

Usage

Uses

Almorexant Hydrochloride is an orally active orexin antagonist (OX1 and OX2 dual receptor antagonist) used in the treatment of insomnia.

Upstream product

• 1296659-30-7 (1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-1,2,3,4-tetrahydro-isoquinoline hydrochloride 
• 871224-68-9 (S)-2-(methylamino)-2-oxo-1-phenylethyl 4-methylbenzenesulfonate 
• 1169801-28-8 (S)-6,7-dimethoxy-1-(4-(trifluoromethyl)phenethyl)-1,2,3,4-tetrahydroisoquinoline acetate 
• 871224-64-5 almorexant 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY PURE TRISUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula 7, which process comprises: the asymmetric transfer hydrogenation of the compound of formula 4 * HX: wherein HX is as decribed in the description; in the presence of

TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE

The present invention relates to the compound of formula 7*acetate (see below), a process for its preparation, and its use

PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i -dicyclohexylphosphino- 2-[(S)-α-(di